The key role of immunomodulatory cytokines for the development of novel NK cell-based cancer therapies
International Review of Cell and Molecular Biology · 2025
DOI: 10.1016/bs.ircmb.2025.01.007 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Review of Cell and Molecular Biology, 2025. Verfasst von Andrea Saez de Cámara und 4 weiteren Autor:innen. Beteiligte Einrichtung: Cell Therapy, Stem Cells and Tissue Group, Biobizkaia Health Research Institute, Barakaldo, Spain; Advanced Therapies Unit. Basque Center for Blood T…. Hauptthemen laut MEDLINE: Killer Cells, Natural, Neoplasms, Cytokines, Immunomodulation. Die Arbeit nennt 209 Literaturangaben.
Abstract (Originalsprache)
Cytokines are crucial modulators of immune responses and have emerged as key components in cancer immunotherapy, particularly concerning Natural Killer (NK) cells. Indeed, the administration of these cytokines have demonstrated significant therapeutic potential in clinical settings. For instance, interleukin-2 (IL-2) has shown efficacy in melanoma and renal cell carcinoma, enhancing anti-tumor immunity but often associated with dose-limiting toxicities. IL-12 has been linked to improved survival rates in various solid tumors by stimulating Th1 responses and activating NK cells. Additionally, IL-15 has gained recognition for its ability to enhance NK cell proliferation and persistence, translating into favorable clinical outcomes in hematological malignancies such as acute myeloid leukemia (AML). Remarkably, cytokines can act synergistically providing stronger effects, and recent advancements have led to the identification of cytokine-induced memory-like NK (CIML-NK) cells. Despite these advancements, significant challenges persist in the translation of cytokine and NK cell therapies into routine clinical practice. The short half-life of recombinant cytokines poses limitations on their effectiveness, requiring high doses that can lead to severe side effects. Additionally, the complexities involved in the large-scale production of cytokines and the development of GMP-grade NK cell-therapies must be overcome. Innovative delivery systems, such as heterodimeric fusion proteins, oncolytic viruses and cytokine gene therapy, have emerged to address these issues, yet further research is needed to optimize these approaches. Collectively, this review underscores the importance of cytokines in harnessing the full potential of NK cells for cancer immunotherapy, and ongoing efforts that aim to optimize cytokine delivery strategies and enhance NK cell manufacturing processes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Cell Therapy, Stem Cells and Tissue Group, Biobizkaia Health Research Institute, Barakaldo, Spain; Advanced Therapies Unit. Basque Center for Blood Transfusion and Human Tissues, Osakidetza, Galdakao, Spain.
- Cell Therapy, Stem Cells and Tissue Group, Biobizkaia Health Research Institute, Barakaldo, Spain; Advanced Therapies Unit. Basque Center for Blood Transfusion and Human Tissues, Osakidetza, Galdakao, Spain; Red de Inmu…
Zitieren
APA
de Cámara, A. S., Barriales, D., Etxebarria, A., Eguizabal, C., & Alvarez, M. (2025). The key role of immunomodulatory cytokines for the development of novel NK cell-based cancer therapies. International Review of Cell and Molecular Biology. https://doi.org/10.1016/bs.ircmb.2025.01.007
Vancouver
de Cámara AS, Barriales D, Etxebarria A, Eguizabal C, Alvarez M. The key role of immunomodulatory cytokines for the development of novel NK cell-based cancer therapies. International Review of Cell and Molecular Biology. 2025. doi:10.1016/bs.ircmb.2025.01.007
BibTeX
@article{deCmara2025,
author = {de Cámara, Andrea Saez and Barriales, Diego and Etxebarria, Anne and Eguizabal, Cristina and Alvarez, Maite},
title = {The key role of immunomodulatory cytokines for the development of novel NK cell-based cancer therapies},
journal = {International Review of Cell and Molecular Biology},
year = {2025},
doi = {10.1016/bs.ircmb.2025.01.007}
}
EUVIMED